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Abstract 
Background: Congenital Heart Defects (CHD) is the most commonly occurring congenital anomaly in Europe and a 
major paediatric health care concern. Investigations are needed to enable identification of CHD risk factors as studies 
have given conflicting results. This study aim was to identify maternal sociodemographic characteristics, behaviours, 
and birth outcomes as risk factors for CHD. This was a population based, data linkage cohort study using anonymised 
data from Northern Ireland (NI) covering the period 2010-2014. The study cohort composed of 94,067 live births with 
an outcome of 1162 cases of CHD using the International Statistical Classification of Diseases and Related Health Prob-
lems (ICD)-10 codes and based on the European Surveillance of Congenital Anomalies (EUROCAT) grouping system 
for CHD. CHD cases were obtained from the HeartSuite database (HSD) at the Royal Belfast Hospital for Sick Children 
(RBHSC), maternal data were extracted from the Northern Ireland Maternity System (NIMATS), and medication data 
were extracted from the Enhanced Prescribing Database (EPD). STATA version 14 was used for the statistical analysis 
in this study, Odds Ratio (OR), 95% Confident intervals (CI), P value, and logistic regression were used in the analysis. 
Ethical approval was granted from the National Health Service (NHS) Research Ethics Committee.
Result: In this study, a number of potential risk factors were assessed for statistically significant association with CHD, 
however only certain risk factors demonstrated a statistically significant association with CHD which included: gesta-
tional age at first booking (AOR = 1.21; 95% CI = 1.04-1.41; P < 0.05), family history of CHD or congenital abnormalities 
and syndromes (AOR = 4.14; 95% CI = 2.47-6.96; P < 0.05), woman’s smoking in pregnancy (AOR = 1.22; 95% CI = 1.04-
1.43; P < 0.05), preterm birth (AOR = 3.01; 95% CI = 2.44-3.01; P < 0.05), multiple births (AOR = 1.89; 95% CI = 1.58-2.60; 
P < 0.05), history of abortion (AOR = 1.12; 95% CI = 1.03-1.28; P < 0.05), small for gestational age (SGA) (AOR = 1.44; 
95% CI = 1.22-1.78; P < 0.05), and low birth weight (LBW) (AOR = 3.10; 95% CI = 2.22-3.55; P < 0.05). Prescriptions and 
redemptions of antidiabetic (AOR = 2.68; 95% CI = 1.85-3.98; P < 0.05), antiepileptic (AOR = 1.77; 95% CI = 1.10-2.81; 
P < 0.05), and dihydrofolate reductase inhibitors (DHFRI) (AOR = 2.13; 95% CI = 1.17-5.85; P < 0.05) in early pregnancy 
also showed evidence of statistically significant association with CHD.
Conclusion: The results of this study suggested that there are certain maternal sociodemographic characteristics, 
behaviours and birth outcomes that are statistically significantly associated with higher risk of CHD. Appropriate 
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Introduction
Congenital heart defects (CHD) is the most commonly 
occurring congenital anomaly in Europe [1], and one of 
the main concerns in paediatric health care which has a 
serious impact on infant mortality rates worldwide [2–4]. 
CHD impacts on health services as well as patients and 
their families [5–7], it represents a major global health 
problem and efforts should be continued to decrease the 
burden of the disease and to offer advice where possible, 
on reduction of risks of CHD.
Identifying the risk factors for CHD is of importance 
as intervening in relation to a particular risk may lead to 
prevention of CHD. Studies have been undertaken in the 
field of CHD risk factor research but have shown con-
flicting results [8]. Therefore, additional investigations 
are needed to enable accurate and robust identification 
of CHD risk factors [9] and to ensure that the required 
interventions are targeted more appropriately.
This study aimed to explore the impact of maternal 
sociodemographic characteristics and lifestyle behav-
iours as risk factors for CHD in Northern Ireland (NI) 
and to contribute to the current evidence on CHD to 
inform public health and social care policy.
NI is ideal for studying the risk factors for CHD as there 
is a single centre for foetal and paediatric cardiology in 
the Royal Belfast Hospital for Sick Children (RBHSC), 
and all children in NI with CHD are first seen at this cen-
tre. Administrative and clinical records of all pregnant 
women in NI and General Practitioner (GP) prescribing 
data are available centrally through the Honest Broker 




This was a population-based cohort study based on sec-
ondary data analysis of linked datasets from HeartSuite 
Database (HSD), Northern Ireland Maternity System 
(NIMATS), and Enhanced Prescribing Database (EPD) 
(These datasets are described in another paper [11]).
Study population and period
The study population includes all live births registered to 
women residing in NI during the period 2010-2014.
Dataset description
For maternal sociodemographic characteristics and 
behaviours; risk factors were collected from details of 
the first booking visit from NIMATS database (92% 
of women gave this information in week 14 or less). Of 
the 96,233 pregnancies, 94,804 gave birth to cases with-
out CHD (98.52%), and 1429 gave birth to CHD cases 
(1.48%). The births were to NI resident women, based 
on NI postcode and registered in the original NIMATS. 
For multiple pregnancies, only the baby with CHD was 
included; if there was no baby with CHD, only the most 
recent pregnancy was included, except where a mother 
had more than one baby with CHD, in which case both 
pregnancies were included, and except in the case of 
multiple births, when all were included.
Data from HSD: the CHD cases are major CHD cases 
recorded in HSD file based on EUROCAT grouping [12] 
using ICD10 codes containing a value between Q20.0 
and Q26.9, except for Q25.0, Q25.6, or Q26. The sample 
includes only NI resident babies.
Medications prescribed and redeemed were obtained 
from EPD: an extract from the EPD, which contains 
detailed information in relation to NI prescriptions 
issued in primary care and redeemed by patients (based 
on British National Formulary (BNF) classification) was 
prepared by the HBS. This extract only includes data 
for NI-resident women registered in NIMATS for the 
period 2010-2014 and is only specific to each woman’s 
Exposure Window (EW), where EW = date of Last Men-
strual Period (LMP) - 30 days and date of LMP + 90 days, 
using the date of each medication prescription. The EW 
begins 30 days prior to the first day of the woman’s LMP 
to enable medication prescriptions taken immediately 
before conception and possibly taken in early pregnancy 
to be included. This timing has been used in the design 
of other studies researching medication transfer in preg-
nancy [13–16].
The aetiology of CHD is apparent among babies with 
chromosomal and genetic syndromes, and among preg-
nant woman who are using vitamin A, anti-diabetic, 
or anti-epileptic medication, therefore these cases 
were excluded in the final file for analysis. This helps to 
increase the sensitivity of this study to assess the asso-
ciation with the other risk factors. However, before 
exclusion the associations between anti-diabetic or 
anti-epileptic medication and CHD were assessed. 222 
prevention policy to target groups with higher risk for CHD may help to reduce CHD prevalence. These results are 
important for policy makers, obstetricians, cardiologists, paediatricians, midwives and the public.
Keywords: Congenital Heart Defects (CHD), Risk Factors, Population Based, Data Linkage, Cohort, Anonymised Data, 
Northern Ireland
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chromosomal and genetic syndromes were excluded 
according to the following ICD10 codes Q90.0-Q93.0, 
Q96.0-Q99.9, Q44.71, Q61.90, Q74.84, Q75.1, Q75.4, 
Q75.81, Q87, Q93.6, and D82.1.
Another 1680 cases in which the pregnant woman 
redeemed a prescription for vitamin A, anti-diabetic, or 
anti-epileptic medication were excluded. The exclusions 
were based on BNF sections. Section 9.6.1 for vitamin A, 
sections 6.1.1 and 6.1.2 for anti-diabetic, and section 4.8 
for anti-epileptic medication (https:// openp rescr ibing. 
net/ bnf/). As the cause of stillbirth was not known in this 
study, 264 pregnancies which resulted in stillbirths were 
excluded.
The final file therefore includes 94,067 pregnancies 
including 1162 CHD cases. The flow of data is shown in 
Fig. 1.
Data linkage
During the study period there were 1605 CHD cases in 
HSD file and of these, 1429 CHD cases were able to be 
linked to NIMATS (HSD file contains only CHD cases, 
mothers in NIMATS which are not linked to HSD are 
assumed to be mothers of cases with no CHD) by HBS 
through deterministic linking using the infant Health 
and Care Numbers (INFANT_HCN). In the EPD extract 
there were 59,406 pregnancies which were linked suc-
cessfully by the author (H.S.) to the NIMATS/HSD file 
using a common identifier (study_id) for both files.
Statistical analysis
Odds Ratio (OR) with 95% confidence interval (CI) and 
P value were used as the association between exposure 
to specific risk factor and the CHD. Another frequently 
used measure of association reported in literature when 
publishing cohort study is risk ratio (RR) [17, 18]. Where 
outcomes are rare, as in the current case (typically <10%) 
the values associated with OR and RR are similar [19, 20]. 
As there is a binary outcome of interest (CHD or not) and 
a number of explanatory covariates (risk factors), logistic 
regression was used. To account for the possible cluster-
ing effects of multiple births, this covariate was included 
within the analysis.
Fig. 1 Flow of the data in the study population NI during the period 2010-2014, including risk factors assessed in the study. CHD=Congenital 
Heart Defects, BMI=Body Mass Index, SGA = Small for Gestational Age, LBW = Low Birth Weight, NIMDM = Northern Ireland Multiple Deprivation 
Measures
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The analysis was only performed when there were at 
least 3 CHD cases occurring after exposure or lack of 
exposure for each potential risk factor. Bivariate and 
multivariable analysis model parameters were estimated 
using maximum likelihood in STATA version 14.
Missing data
Complete subject analysis was adopted and subjects 
with missing data in any potential risks were excluded 
from the analysis. The multivariable model is based on 
90,079 pregnancies out of 94,067 pregnancies in the 
final file (approximately 96%). No imputation was con-
ducted in this study and all percentages of missing val-
ues for each potential risk were presented.
Covariates in the study
Those which have been examined for evidence of sta-
tistically significant association with CHD are gesta-
tional age at first booking, rural residency, pregnancy 
deprivation using Northern Ireland Multiple Depriva-
tion Measures (NIMDM), woman’s age at booking, par-
ity, family history of CHD or congenital abnormalities 
and syndromes, preterm birth, multiple births, history 
of abortion (whether spontaneous or induced), small 
for gestational age (SGA), low birth weight (LBW) 
(birth weight < 2500 g), gender, unplanned pregnancy, 
woman’s Body Mass Index (BMI), woman’s alcohol 
consumption, woman’s smoking in pregnancy, wom-
an’s self-reported usage of folic acid (FA) and vitamins 
or any other group of medications, prescriptions and 
redemptions of FA and vitamin, mental health medica-
tion (MHM), and other medications.
Results
Table 1 shows the association between the 18 potential 
risk factors assessed in this study and CHD using OR, 
95% CI, and P value. Women who booked their first 
antenatal appointment after 14 weeks of pregnancy had 
an increased risk of their offspring developing CHD 
(P = 0.01). Family history of CHD or history of CHD 
and congenital abnormalities and syndromes showed 
strong evidence of statistically significant positive 
association with CHD (P < 0.01). The positive associa-
tion with CHD also increased significantly in pregnant 
women who smoked (P < 0.05).
Women’s usage of medications in pregnancy (based 
on self-reported data taken from NIMATS), showed 
that taking other medications (other medications 
in NIMATS are any medication except FA and vita-
mins) had statistically positive association with CHD 
(P < 0.05). Medications from EPD are categorised 
into non-medication, FA and vitamin, dihydrofolate 
reductase inhibitors (DHFRI), MHM, and other medi-
cations (other medications in EPD are any medication 
that is not FA, DHFRI, or MHM). Using the EPD file 
showed that prescription and redemption of MHM has 
no significant association with CHD (P = 0.40). In con-
trast, DHFRI have shown a significantly increased risk 
of developing CHD (P < 0.05). However, FA supplement 
alone showed no significant protective association with 
CHD (P > 0.05).
Before excluding pregnancies which were exposed to 
antidiabetic and antiepileptic medications, their associa-
tion with CHD was assessed, and both antidiabetic and 
antiepileptic medications showed statistically significant 
association with CHD with (AOR = 2.68; 95% CI = 1.85-
3.98; P < 0.01) and (AOR = 1.77; 95% CI = 1.10-2.81; 
P < 0.02), respectively.
Other potential risk factors related to the baby were 
examined, and data showed evidence of positive associa-
tion with CHD and preterm birth (P < 0.01), LBW (birth 
weight < 2500 g) (P < 0.01), SGA (P < 0.01), and multiple 
births (P < 0.01). There was strong evidence of a posi-
tive association between. history of abortion and CHD 
(P < 0.05).
Discussion
Women who booked their first antenatal appointment 
after 14 weeks of pregnancy had an increased risk of their 
offspring developing CHD, this may be because provi-
sion of antenatal care (ANC) before 14 weeks allows 
guidance to be provided at an early stage on modifiable 
lifestyle risks such as smoking, alcohol consumption and 
using certain teratogens. Early ANC also captures DM 
and could enhance blood glycaemic control. It is there-
fore crucial for ensuring optimal care and good maternal 
and foetal health [21]. Late booking (which delays ANC) 
may delay dealing with the risks outlined above, most of 
which have shown an increased association with CHD in 
offspring. The study suggests that health service planning 
should investigate the reasons behind late first booking 
appointments and ensure a policy to reduce these due 
to the association with CHD and other potential adverse 
outcomes for both babies and pregnancies.
There was no higher risk of developing CHD among 
infants whose mothers lived in rural areas in compari-
son to urban areas. The literature showed conflicting 
results regarding the association between rural or urban 
residency and CHD in offspring [22, 23]. Being catego-
rised in the most deprived group based on NIMDM as 
a proxy of SES was not shown to have a statistically sig-
nificant association with CHD. And there is no evidence 
that differences in SES (based on area level measures) 
affect the occurrence of CHD in NI. However, the find-
ings of this study may be consistent with a finding from 
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Table 1 Association between potential risk factors and CHD in NI (2010-2014) using OR, 95% CI, and P value (bivariate/multivariable 
analysis)





1. Gestational age at first booking
 ≤14 weeks 85,126 1043 86,169 92
 >14 weeks 7779 119 7898 8 1.25 (1.03-1.51) 0.02 1.21 (1.04-1.41) 0.01
 Missing 0 0 0 0
 Total 92,905 1162 94,067 100
2. Rural residency
 Urban 59,637 746 60,383 64.19
 Rural 31,999 414 32,413 34.46 1.03 (0.92-1.17) 0.58 1.04 (0.92-1.18) 0.52
 Missing # # 1271 1.35
 Total # # 94,067 100
3. Deprivation using NIMDM2010
 Quintile 5 (Least deprived) 14,167 180 14,347 15.25
 Quintile 4 17,880 218 18,098 19.24 0.96 (0.79-1.17) 0.68 0.94 (0.77-1.15) 0.56
 Quintile 3 18,971 259 19,230 20.44 1.07 (0.89-1.30) 0.46 1.03 (0.84-1.25) 0.38
 Quintile 2 19,529 225 19,754 21.0 0.91 (0.74-1.10) 0.33 0.86 (0.70-1.05) 0.14
 Quintile 1 (Most deprived) 21,157 279 21,436 22.79 1.04 (0.86-1.25) 0.70 0.97 (0.80-1.19) 0.58
 Missing # # 1202 1.28
 Total # # 94,067
4. Parity
 P0 (Nulliparous) 33,071 469 33,540 35.66
 P1 33,852 403 34,255 36.42 0.84 (0.73-0.96) 0.01 0.77 (0.70-0.88) 0.01
 P2 16,888 173 17,061 18.14 0.72 (0.61-0.86) <0.01 0.69 (0.59-0.79) <0.01
 P3 5932 64 5996 6.37 0.76 (0.59-0.99) 0.04 0.75 (0.57-0.99) 0.04
 P4 1764 28 1792 1.91 1.12 (0.76-1.64) 0.57 1.01 (0.71-1.44) 0.41
 ≥ P5 (Grand multipara) 970 17 987 1.05 1.24 (0.76-2.01) 0.39 1.24 (0.76-2.01) 0.39
 Missing # # 436 0.46
 Total # # 94,067
5. Woman’s age at first booking
 25-29 years 25,968 342 26,310 27.97
 20-24 years 14,863 167 15,030 15.98 0.85 (0.71-1.32) 0.09 0.80 (0.66-0.98) 0.05
 30-34 year 28,919 370 29,289 31.14 0.97 (0.84-1.13) 0.70 0.98 (0.85-1.15) 0.69
 35-39 years 15,280 186 15,466 16.44 0.92 (0.77-1.11) 0.39 0.90 (0.75-1.09) 0.27
 40+ years 3091 36 3127 3.32 0.88 (0.63-1.25) 0.49 0.84 (0.59-1.21) 0.36
 <20 years 4738 58 4796 5.10 0.93 (0.70-1.23) 0.61 0.87 (0.64-1.17) 0.35
 Missing # # 49 0.05
 Total # # 94,067
6. History of CHD or congenital abnormalities and syndromes
 No history of CHD or congenital abnormalities and 
syndromes
81,641 841 82,482 87.68
 Only history of CHD 6310 237 6547 6.96 3.65 (3.15-4.22) <0.01 3.62 (3.11-4.21) <0.01
 Only history of congenital abnormalities and syn-
dromes
4593 68 4661 4.95 1.44 (1.12-1.84) <0.01 1.28 (0.99-1.67) 0.05
 History of CHD and congenital abnormalities and 
syndromes
361 16 377 0.40 4.3 (2.60-7.13) <0.01 4.14 (2.47-6.96) <0.01
 Missing 0 0 0 0
 Total 92,905 1162 94,067
7. Woman’s smoking in pregnancy
 No smoking 77,453 933 78,386 83.33
 Smoking 15,383 228 15,611 16.60 1.23 (1.06-1.42) <0.01 1.22 (1.04-1.43) 0.02
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Table 1 (continued)





 Missing # # 70 0.07
 Total # # 94,067
8. Alcohol consumption
 No alcohol consumption 91,910 1149 93,059 98.93
 Alcohol consumption 914 12 926 0.98 1.05 (0.59-1.86) 0.87 0.96 (0.53-1.76) 0.81
 Missing # # 82 0.09
 Total # # 94,067
9. Woman’s BMI
 Normal 44,395 541 44,936 47.77
 Overweight 26,041 329 26,370 28.03 1.04 (0.90-1.19) 0.61 1.04 (0.79-1.10) 0.59
 Obese 15,027 186 15,213 16.17 1.02 (0.86-1.20) 0.86 1.01 (0.71-1.01) 0.73
 Morbidly obese 1924 22 1946 2.07 0.94 (0.61-1.44) 0.77 0.77 (0.33-1.45) 0.59
 Underweight 2033 31 2064 2.19 1.25 (0.87-1.80) 0.23 1.17 (0.69-1.55) 0.19
 Missing 3485 53 3538 3.76
 Total 92,905 1162 94,067
10. Unplanned pregnancy
 Planned 63,938 792 64,730 68.81
 Unplanned 26,535 330 26,865 28.56 1.00 (0.88-1.14) 0.95 1.01 (0.87-1.18) 0.87
 Missing 2432 40 2472 2.63
 Total 92,905 1162 94,067
11. Woman’s self-reported usage of medication
 None 5103 51 5154 5.48
 FA and vitamins 68,878 849 69,727 74.12 1.23 (0.93-1.64) 0.15 1.11 (0.85-1.55) 0.13
 Other medications** 18,924 262 19,189 20.40 1.39 (1.02-1.87) 0.03 1.14 (1.01-1.66) 0.02
 Missing 0 0 0 0
 Total 92,905 1162 94,067
12. Prescriptions and redemptions of medications in EPD
 No redemptions 36,195 456 36,651 38.96
 FA and Vitamin 9883 120 10,003 10.63 0.96 (0.79-1.18) 0.72 0.89 (0.77-1.18) 0.61
 DHFRI # # # # 2.56 (1.13-5.80) 0.02 2.13 (1.17-5.85) 0.01
 MHM 6873 103 6976 7.42 1.19 (0.96-1.48) 0.11 1.33 (0.87-1.68) 0.10
 Other medications*** # # # # 0.95 (0.84-1.09) 0.52 0.98 (0.77-1.18) 0.42
 Missing 0 0 0 0
 Total 92,905 1162 94,067
13. Preterm birth
 ≥ 37 weeks (Term) 86,240 943 87,183 92.68
 <37 weeks (Preterm) 6587 218 6805 7.23 3.03 (2.61-3.51) <0.01 3.01 (2.44-3.01) <0.01
 Missing # # 79 0.08
 Total # # 94,067
14. Multiple birth
 Single birth 89,732 1085 90,817 96.55
 Multiple birth 3173 77 3250 3.45 2.01 (1.59-2.54) <0.01 1.89 (1.58-2.60) <0.01
 Missing 0 0 0
 Total 92,905 1162 94,067
15. History of previous miscarriage or termination of pregnancy
 No history of abortion 67,230 803 68,033 72.32
 History of abortion 25,247 351 25,598 27.21 1.16 (1.03-1.32) 0.02 1.12 (1.03-1.28) 0.02
 Missing # # 436 0.46
 Total # # 94,067
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a meta-analysis, which showed no clear relationship 
between SES and CHD in developed countries [24].
Parity was not shown to have a statistically significant 
association with CHD, meta-analysis showed no statisti-
cally significant association between parity (comparing 
highest to lowest) and CHD in studies conducted after 
2010 [25] and this is consistent with the findings of this 
study.
Regarding the woman’s age at first booking, no statis-
tically significant association was shown between older 
women (>40 years) and CHD. These results are challeng-
ing as they do not support earlier research [26, 27]. How-
ever, they do support more recent research reporting a 
lack of positive association between CHD and advanced 
age [28]. This data may alleviate anxiety amongst older 
mothers and reduce the number of referrals for early 
echocardiography to detect CHD that are primarily 
based on older age. It may also reassure older women 
that their age in itself does not confer additional risk of 
CHD, and it may support the belief that women in this 
age group take extra care during their pregnancy to pro-
tect their baby [28].
There was evidence in this study of a statistically sig-
nificant positive association between maternal smoking 
and CHD. This finding suggests that population-based 
prevention strategies targeting smoking cessation in 
pregnancy should highlight this message. A decrease 
in maternal smoking during pregnancy could result 
in decreased risk of CHD. The positive association of 
maternal smoking with CHD found in this study is 
consistent with findings from National Birth Defects 
Prevention Study (NBDPS) [29]. The NBDPS database 
identified an increased risk of developing specific sub-
types of CHD in offspring of pregnant women who 
smoked [29], and a meta-analysis showed a positive 
association between maternal smoking during preg-
nancy and risk of CHD [30]. The mechanisms through 
which smoking may cause CHD are still to be clearly 
identified. It has been postulated that maternal smok-
ing has harmful effects on the development of the foe-
tus; carbon monoxide and nicotine induce hypoxia and 
reduce the supply of essential nutrients to the embryo 
[31, 32]. Additionally, common components of ciga-
rette smoke such as polycyclic aromatic hydrocarbons 
are suspected teratogens in laboratory tests on humans 
and animals [33, 34]. From a public health policy per-
spective, finding from this study and others may fuel 
the need to ring-fence funding for smoking cessation 
prenatally and antenatally.
Table 1 (continued)






 No SGA 83,513 991 84,504 89.83
 SGA 8964 163 9127 9.70 1.53 (1.30-1.81) <0.01 1.44 (1.22-1.78) <0.01
 Missing # # 436 0.46
 Total # # 94,067
17. Low birth weight (<2500 g)
 No low birth weight 87,552 971 88,523 94.11
 Low birth weight 3684 134 3818 4.06 3.28 (2.73-3.94) <0.01 3.1 (2.22-3.55) <0.01
 Missing 1669 57 1726 1.83
 Total 92,905 1162 94,067
18. Gender
 Male 47,460 609 48,069 51.10
 Female 45,427 553 45,980 48.88 0.95 (0.84-1.07) 0.37 0.89 (0.67-1.12) 0.32
 Missing 18 0 18 0.02
 Total 92,905 1162 94,067
# Disclosure control by the researcher for numbers less than 10, as per the process laid out by HBS
SGA small for gestational age, MHM mental health medication, FA folic acid, DHFRI Di hydro folate reductase inhibitors
*Adjusted OR for gestational age at first booking, urban/rural residency, deprivation using NIMDM, parity, woman’s age at first booking, unplanned pregnancy, history 
of CHD or congenital abnormalities and syndromes, woman’s BMI, woman’s smoking, alcohol consumption, woman’s self-reported usage of medication, preterm baby, 
multiple birth, prescription and redemption of medication, history of abortion, SGA, LBW, and gender
**other medications in NIMATS are any medication except FA and vitamins
***other medications in EPD are any medication that is not FA, DHFRI, or MHM
The multivariable model is based on 90,079 pregnancies out of 94,067 pregnancies in the final file (approximately 96%)
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No statistically significant association with CHD was 
shown for alcohol consumption in this study. While this 
result is important it should not be interpreted as evi-
dence that maternal drinking is safe, as it is known that 
prenatal exposure to low levels of alcohol, such as a sin-
gle unit, can result in foetal alcohol syndrome (FAS) [35]. 
Nevertheless, no significant association between alcohol 
consumption in pregnancy and CHD was found in two 
recent meta-studies with a large sample size; these find-
ings are consistent with those of the current study [36, 
37].
Previous meta-analysis demonstrated that offspring 
of women with a history of abortion (whether sponta-
neous or induced) had a higher risk of developing CHD 
[38], a finding which was repeated in this study. While 
the specific biological mechanism which underlies the 
link between a history of previous abortion and the risk 
of CHD is still unclear, it has been suggested that history 
of abortion can cause mental stress to mothers [39], and 
literature [40, 41] found that mothers who were exposed 
to stress during pregnancy might have an increased risk 
of CHD in their offspring.
Family history of CHD or congenital abnormalities 
and syndromes is associated with increased risk of CHD. 
This finding has relevance for any preventative policy 
for CHD, such as pre-conceptional counselling for par-
ents with a family history of CHD. Midwives routinely 
collect this data and identify risk factors for congenital 
anomalies. However, evidence from literature and this 
study may lead to clinical policy developments resulting 
in more screening referrals for foetal cardiology at book-
ing and more midwifery input to counselling mothers 
prior to tests. The positive association of family history 
of CHD or congenital abnormalities and syndromes and 
CHD found in this study is consistent with those of other 
studies in Denmark, Canada, and USA [42, 43].
The study has shown statistically positive association 
between CHD and prescription and redemption of FA 
antagonists group of medications (including antiepileptic 
and DHFRI) in early pregnancy. Clinicians in particular 
will be interested in this result as it may help to guide 
their prescription practice and midwives booking moth-
ers into the antenatal clinic need to be alerted to this risk 
factor. This result is consistent with the findings from 
previous studies that assessed the association between 
FA antagonists and CHD, which showed that usage of FA 
antagonists (either DHFRI or antiepileptic) to be associ-
ated with an increased risk of CHD [44–46].
The pharmacological plausibility of this positive asso-
ciation confirms the importance of this finding at pub-
lic health policy level. Impaired folate metabolism has 
been found to affect cardiac neural crest cell formation 
and migration and it has been suggested that this might 
interfere with heart development [47–50]. Impaired FA 
transport has led to extensive death of apoptotic cells in 
the developing heart [51].
Unplanned pregnancy has been shown to have no 
significant positive association with CHD. This is an 
important finding, as there is a scarcity of studies that 
address this question. It should be noted, however, that 
unplanned pregnancy may be more likely to be associ-
ated with certain behaviour in early pregnancy such as 
smoking, lower educational attainment [52], and out-
comes such as preterm labour [53], all of which are asso-
ciated with a higher risk of CHD.
FA supplementation showed no protective effect for 
CHD. This finding, which is based on data from two dif-
ferent sources (NIMATS and EPD), is surprising as most 
previous research has shown a protective effect for FA 
[54] and there is a plausible biological mechanism to jus-
tify this protective effect. This finding may call into ques-
tion any policy which aims to reduce CHD prevalence 
by imposing population based folic acid fortification 
in NI. However, this lack of protective effect should be 
received with caution; as suggested by Hobbs et al. [55], 
the absence of a protective association between FA and 
CHD cannot be asserted without further analysis of rel-
evant environmental and genetic factors. Furthermore, 
the finding that FA antagonists (DHFRI and antiepilep-
tics) are associated with increased risk of CHD may also 
indicate the importance of FA in CHD causation. The 
finding that FA had no protective effect also could be 
due to the misclassification of exposure, in that the level 
of FA required for individuals had already been attained; 
molecular techniques are needed to test this theory. 
However, it is possible that the finding could reflect a true 
absence of protective effect, as in fact has been shown by 
a number of studies that have found no significant pro-
tective effect of FA supplementation on CHD [56, 57].
This study showed no statistically significant associa-
tion between maternal obesity and risk of CHD. How-
ever, it must be noted that this finding conflicts with 
previous literature in which obese pregnant women were 
found to have a significantly increased risk of CHD [58–
60]. It is important to note that the mechanisms which 
explain the relationship between maternal obesity and 
CHD are unclear, although there is an argument that 
women who are obese may have Diabetes Mellitus (DM), 
which is a known risk factor for CHD [61]. The findings 
of this study support this argument as all DM cases were 
excluded from the analysis allowing the independent 
assessment of obesity as a risk factor for CHD.
In this study, certain factors are categorised as fac-
tors related to the child birth outcome, these were: 
SGA; multiple births; LBW; whether term or preterm; 
and gender. It was interesting to note that there had 
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been statistically significant association between all 
those factors (except gender) and CHD. The literature 
supports these findings and shows that there are sig-
nificant differences in the occurrence of CHD among 
SGA [62, 63], multiple births [64];, LBW [65], or pre-
term birth [63, 66, 67]. Multiple birth status potentially 
affects intrauterine growth and carries a higher risk 
of premature birth [68]. The mechanism behind why 
these groups carries a higher risk of having an infant 
with CHD is not clear. These groups are important to 
be aware of as they may need to be considered in the 
implementation of any preventative policy in relation 
to CHD. Given that some babies are more at risk of 
having CHD than others, considering these categories 
is essential to facilitate early detection (via appropriate 
diagnostic procedures) and appropriate intervention. 
From a clinical perspective, many CHDs are not diag-
nosed antenatally and are identified at birth or shortly 
thereafter. Early diagnosis is important in providing an 
opportunity for early treatment and the prevention of 
disabilities and death [69], therefore assessing risk fac-
tors and clinical decision making are critical factors to 
be taken into consideration when formulating CHD 
policies. This study showed no significant association 
between gender and CHD, and the literature on gender 
has shown conflicting results regarding its association 
with CHD [43, 70].
It is also crucial to comment on the finding that anti-
diabetic medication prescription during pregnancy is 
associated with CHD. This finding is highly significant 
as it suggests that putting women who have DM at the 
heart of any preventative policy for CHD may be useful. 
This result aligns with the current literature, which has 
shown positive association between pre-existing diabe-
tes and CHD [61, 71–74]. The possible causal mechanism 
for this positive association is poorly understood but 
the main hypothesis clarifying the positive association 
between maternal DM and CHD in offspring is that a ter-
atogenic effect on the developing heart may be caused by 
excess glucose [75]. Excess glucose may lead to epigenetic 
changes that would affect gene expression in the develop-
ing embryo [76].
The control of blood glucose in pregnancy could be 
one of the preventative measures for the development of 
CHD [77]. Blood glucose control requires regular blood 
check, diet control, exercise, and subsequent diabetic 
medication adjustment. Antidiabetic medication pre-
scribed in this study included oral hypoglycaemic medi-
cation which may lack efficiency to overcome insulin 
resistance in pregnancies [78] and hence does not con-
trol for blood glucose level. According to the American 
Diabetes Association guidelines, diabetic women tak-
ing oral hypoglycemic medication might be at risk of 
treatment failure and they should switch to insulin when 
they are pregnant [79]. It should also be mentioned that 
there is a signal in the literature which showed that oral 
hypoglycemic medication such as metaformin might be 
associated with increased risk of CHD [80]. In addition, 
although women were prescribed antidiabetic medica-
tion, its prescription in this study might not reflect usage 
of antidiabetic medications (or any other medications) 
and literature has shown that there is discontinuation 
of oral antidiabetic medicines during pregnancy among 
large number of pregnant women [81, 82].
Most of the study covariates did have 0% missing val-
ues, and a few of them showed less than 4% missing val-
ues, which gives credibility to the study results (Table 1). 
The study provides an overview of the profile of pregnant 
women in NI which is useful for researchers. For exam-
ple, it showed that 65% of pregnant women in NI live 
in urban areas, 15.6% smoke, and 64.7% have a planned 
pregnancy.
It should be noted that the livebirth prevalence of CHD 
in this data is higher than others in Europe. This may be 
due to complete ascertainment of both early and later 
diagnosed cases in the paediatric cardiology database 
used in this study as well as the fact that during the study 
period NI was one of the few European countries where 
termination of pregnancy for fetal anomaly was illegal.
Strengths and limitations
This is the first population based study to use big data 
from linked administrative and clinical databases that 
cover the entire population in NI during the period 2010-
2014 to identify risk factors for CHD, with a large sample 
size of 94,067 pregnancies and 1162 CHD cases. Differ-
ent risk factors for developing CHD related to maternal 
sociodemographic characteristics, behaviours and birth 
outcomes were assessed and the study was able to adjust 
for several significant covariates. CHD diagnoses in this 
study were obtained from RBHSC which is the only 
centre in NI in which cases are examined by echocar-
diograph and diagnosed by paediatric cardiologists. Two 
studies using UK data reported good positive predictive 
values for ICD-10 codes (PPVs ≥90%) [83, 84]. There was 
high ascertainment for CHD diagnosis, all HSD cases 
underwent echocardiography by paediatric cardiologists 
using the same echo machines and following the same 
diagnostic criteria, thereby limiting the chance of case 
misclassification. Most of the study covariates have a low 
percentage of missing values which suggests that the data 
used is high quality. The study provides an overview of 
the profile of pregnant women in NI which is useful for 
researchers.
Recall bias has been avoided in this study by using pro-
spectively collected data, as recall bias is expected when 
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exposure data is collected retrospectively [85]. Retro-
spectively collected data with questionnaires may also 
involve interviewer bias which is also avoided in this 
study. However, linkage between CHD cases from HSD 
to NIMATS was not able to link 10.9% of the CHD cases 
and the exclusion of those cases from the analysis may 
have led to under-ascertainment of exposures or out-
comes, and might have led to selection bias. Women who 
moved later in pregnancy and gave birth in NI are all 
included in the study, however there is no data on women 
and their births outcome for those who gave birth out-
side NI during the study period.
However, the study results are as precise as possible 
using available data and rigid inclusion and exclusion cri-
teria and specifying the importance of the first trimester 
in highlighting any temporal relationship between poten-
tial risk and outcome, which would need to be considered 
in any future discussion of causation. Caution should be 
taken when applying the results of this study to other 
populations due to differences between populations, 
study period, and methodologies.
It should be noted that this an association rather than 
causation study, in future studies causation might be 
assessed more robustly inferred by the introduction 
of graphical models based on Directed Acyclic Graph 
(DAG) and using an epidemiological framework such as 
Bradford-Hill criteria to assess possible cause and effect.
The risk for CHD measured in this study is based on 
live birth estimates and no estimation was calculated 
based on stillbirths and termination of pregnancy, and 
this is one of the study limitations. Ideally, all foetuses 
with stillbirths and termination of pregnancy including 
termination of pregnancy for foetal anomalies (TOPFA) 
should be included, specifying those who have CHD. 
TOPFA could not be included as TOPFA was not permit-
ted in NI unless: “a woman’s life is at risk or where there 
is a risk of a serious and adverse long term or permanent 
effect on her physical or mental health” [86].
Although accurate information about TOPFA in NI 
is not available, reports covering the period 2010-2014 
have shown that some pregnant women travelled from 
NI to England, Scotland or Wales to have an abortion, 
including TOPFA. There were 4652 abortions performed 
in England and Wales on women who had travelled 
from NI during the period 2010-2014 [87]. It is not 
known how many of those cases have CHD but exclu-
sion of these cases from the analysis may have affected 
the results. Stillbirths were not included in the study as 
HSD and NIMATS do not include information about 
stillbirth cases which are diagnosed as CHD (This prac-
tice requires post-mortem for all stillbirths, and this was 
not the practice in NI during the study period). However, 
excluding stillbirths from the current study would be 
expected to have a minimal effect as stillbirth occurs in 
approximately 264 pregnancies which represents 0.27% 
of all pregnancies in this study, and congenital abnormal-
ities including CHD account for only 12-14% of stillbirths 
[88, 89]. The study estimation does not consider pregnan-
cies which end in miscarriage or ectopic pregnancy. The 
ectopic pregnancy rate in the UK is 11 per 1000 [90] and 
1 out of 4 pregnancies ends with miscarriage [91]. How-
ever, it is not common practice to include them in stud-
ies as it is difficult to identify the cause of miscarriage or 
whether the foetus in an ectopic pregnancy had a heart 
problem or not.
There is always a possibility of exposure misclassifica-
tion in relation to a number of risk factors assessed in this 
study. For example, pregnant women tend to underesti-
mate their smoking behaviour when self-reporting [92]. 
Moreover, the study did not examine the factors which 
may affect total smoking exposure such as environmen-
tal tobacco smoke. Future research using serum cotinine 
measurement to validate smoking risk will give more 
accurate information regarding the association between 
smoking in pregnancy and CHD.
Residual confounding by confounders such as ethnic-
ity [93], certain environmental exposure [94], method of 
conception [95], and preeclampsia [96] may still be pre-
sent, but the association between the potential residual 
confounders and CHD, must be strong and specific for 
CHD to have the potential to alter the findings of this 
study. In this study, several risks were assessed simulta-
neously leading to multiple testing issues and potential 
chance findings. No adjustment was made for multiple 
testing in this study as doing so may cause significant 
clinical associations to be lost. This approach has been 
adopted in other studies [12, 97].
Confounding by indication is one of the most impor-
tant limitations of this study, in which individuals who 
were exposed to drugs may have experienced a contrary 
outcome (i.e. CHD) because they are more ill than oth-
ers. Whether or not the pregnant women took the drugs 
as prescribed is not confirmed, as redemption of pre-
scription does not necessarily indicate the medication 
was taken. There is therefore a risk of exposure mis-
classification, possibly leading to drug use overestima-
tion. This has been considered in the study design in 
which the exposure period goes back to only one month 
before LMP in line with the literature which suggested 
that: “prescriptions given in the period prior to 1 month 
before the LMP would have resulted in a greater percent-
age of women who do not use medication during preg-
nancy” [98].
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Conclusion
The study provides data on the maternal sociodemo-
graphic characteristics, behaviours and birth outcomes as 
risk factors for CHD in NI during the period 2010-2014, 
which is important for public health policy, maternity 
service providers, researchers, clinicians, and the public.
The identified association and possible causation 
should be understood and discussed on logical plau-
sibility, and within the overall context of the avail-
able evidence to promote CHD prevention. Potential 
risk factors which did not show positive significant 
association with CHD in this study should always be 
understood within the same context. The study has 
strengths but it has limitations which may also need 
to be addressed in future studies which involve linking 
big databases. Other risk factors which are not found in 
the study data and hence were not assessed should be 
assessed in future studies.
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